Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus
Authors:
- Alexander ThomasATAlexander Thomas
- Dean J. KereiakesDean J. Kereiakes
- Andreas BaumbachABAndreas Baumbach
- Cody PietrasCPCody Pietras
- Ovidiu DresslerODOvidiu Dressler
- Michael CurtisMCMichael Curtis
- Barry BertoletBBBarry Bertolet
- Pieter C. SmitsPSPieter C. Smits
- Victor Alfonso Jiménez DíazVDVictor Alfonso Jiménez Díaz
Open Access
- 11 April 2022
- journal article
- research article
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 1 (2)
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Everolimus-Eluting Xience V/Promus Versus Zotarolimus-Eluting Resolute Stents in Patients With Diabetes MellitusJACC: Cardiovascular Interventions, 2014
- Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes MellitusJACC, 2014
- Percutaneous Coronary Intervention in Patients With DiabetesJournal of Diabetes Science and Technology, 2014
- Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trialsInternational Journal of Cardiology, 2013
- Drug-Eluting Coronary-Artery StentsNew England Journal of Medicine, 2013
- Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trialsBMJ, 2012
- Plaque Composition and Clinical Outcomes in Acute Coronary Syndrome Patients With Metabolic Syndrome or DiabetesJACC: Cardiovascular Imaging, 2012
- Outcomes in Diabetic and Nondiabetic Patients Treated With Everolimus- or Paclitaxel-Eluting StentsJACC, 2010
- Vascular Responses to Drug Eluting StentsArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Diabetes and Vascular DiseaseCirculation, 2003